Potential real-world benefit of semaglutide 2.4 mg on cardiovascular outcomes in the UK based on the SELECT trial
Event:
ESC Congress 2025
Topic:
Electronic Health Records & Hospital Information Systems
Session:
Using big data to drive cardiovascular innovations
